257 related articles for article (PubMed ID: 33533253)
1. Angler Peptides: Macrocyclic Conjugates Inhibit p53:MDM2/X Interactions and Activate Apoptosis in Cancer Cells.
Philippe GJ; Mittermeier A; Lawrence N; Huang YH; Condon ND; Loewer A; Craik DJ; Henriques ST
ACS Chem Biol; 2021 Feb; 16(2):414-428. PubMed ID: 33533253
[TBL] [Abstract][Full Text] [Related]
2. Cell Membrane Composition Drives Selectivity and Toxicity of Designed Cyclic Helix-Loop-Helix Peptides with Cell Penetrating and Tumor Suppressor Properties.
Philippe GJ; Gaspar D; Sheng C; Huang YH; Benfield AH; Condon ND; Weidmann J; Lawrence N; Löwer A; Castanho MARB; Craik DJ; Troeira Henriques S
ACS Chem Biol; 2019 Sep; 14(9):2071-2087. PubMed ID: 31390185
[TBL] [Abstract][Full Text] [Related]
3. Development of cell-penetrating peptide-based drug leads to inhibit MDMX:p53 and MDM2:p53 interactions.
Philippe G; Huang YH; Cheneval O; Lawrence N; Zhang Z; Fairlie DP; Craik DJ; de Araujo AD; Henriques ST
Biopolymers; 2016 Nov; 106(6):853-863. PubMed ID: 27287767
[TBL] [Abstract][Full Text] [Related]
4. Delivery to, and Reactivation of, the p53 Pathway in Cancer Cells Using a Grafted Cyclotide Conjugated with a Cell-Penetrating Peptide.
Philippe GJ; Huang YH; Mittermeier A; Brown CJ; Kaas Q; Ramlan SR; Wang CK; Lane D; Loewer A; Troeira Henriques S; Craik DJ
J Med Chem; 2024 Jan; 67(2):1197-1208. PubMed ID: 38174919
[TBL] [Abstract][Full Text] [Related]
5. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.
Liu M; Li C; Pazgier M; Li C; Mao Y; Lv Y; Gu B; Wei G; Yuan W; Zhan C; Lu WY; Lu W
Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14321-6. PubMed ID: 20660730
[TBL] [Abstract][Full Text] [Related]
6. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
[TBL] [Abstract][Full Text] [Related]
7. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.
Shangary S; Ding K; Qiu S; Nikolovska-Coleska Z; Bauer JA; Liu M; Wang G; Lu Y; McEachern D; Bernard D; Bradford CR; Carey TE; Wang S
Mol Cancer Ther; 2008 Jun; 7(6):1533-42. PubMed ID: 18566224
[TBL] [Abstract][Full Text] [Related]
8. A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins.
Soares J; Raimundo L; Pereira NA; dos Santos DJ; Pérez M; Queiroz G; Leão M; Santos MM; Saraiva L
Pharmacol Res; 2015; 95-96():42-52. PubMed ID: 25814188
[TBL] [Abstract][Full Text] [Related]
9. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of Putative Helix-Breaking Amino Acids in the Design of Novel Stapled Peptides: Exploring Biophysical and Cellular Permeability Properties.
Partridge AW; Kaan HYK; Juang YC; Sadruddin A; Lim S; Brown CJ; Ng S; Thean D; Ferrer F; Johannes C; Yuen TY; Kannan S; Aronica P; Tan YS; Pradhan MR; Verma CS; Hochman J; Chen S; Wan H; Ha S; Sherborne B; Lane DP; Sawyer TK
Molecules; 2019 Jun; 24(12):. PubMed ID: 31226791
[TBL] [Abstract][Full Text] [Related]
11. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
[TBL] [Abstract][Full Text] [Related]
12. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
[TBL] [Abstract][Full Text] [Related]
13. Enhancing the Cell Permeability of Stapled Peptides with a Cyclic Cell-Penetrating Peptide.
Dougherty PG; Wen J; Pan X; Koley A; Ren JG; Sahni A; Basu R; Salim H; Appiah Kubi G; Qian Z; Pei D
J Med Chem; 2019 Nov; 62(22):10098-10107. PubMed ID: 31657556
[TBL] [Abstract][Full Text] [Related]
14. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
15. mRNA display selection of an optimized MDM2-binding peptide that potently inhibits MDM2-p53 interaction.
Shiheido H; Takashima H; Doi N; Yanagawa H
PLoS One; 2011 Mar; 6(3):e17898. PubMed ID: 21423613
[TBL] [Abstract][Full Text] [Related]
16. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy.
Liu Y; Wang X; Wang G; Yang Y; Yuan Y; Ouyang L
Eur J Med Chem; 2019 Aug; 176():92-104. PubMed ID: 31100649
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of the first small molecule inhibitor of MDMX.
Reed D; Shen Y; Shelat AA; Arnold LA; Ferreira AM; Zhu F; Mills N; Smithson DC; Regni CA; Bashford D; Cicero SA; Schulman BA; Jochemsen AG; Guy RK; Dyer MA
J Biol Chem; 2010 Apr; 285(14):10786-96. PubMed ID: 20080970
[TBL] [Abstract][Full Text] [Related]
18. A tetrameric protein scaffold as a nano-carrier of antitumor peptides for cancer therapy.
Ma B; Niu F; Qu X; He W; Feng C; Wang S; Ouyang Z; Yan J; Wen Y; Xu D; Shao Y; Ma PX; Lu W
Biomaterials; 2019 Jun; 204():1-12. PubMed ID: 30861422
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.
Zheng GH; Shen JJ; Zhan YC; Yi H; Xue ST; Wang Z; Ji XY; Li ZR
Eur J Med Chem; 2014 Jun; 81():277-88. PubMed ID: 24852275
[TBL] [Abstract][Full Text] [Related]
20. Design and development of high affinity dual anticancer peptide-inhibitors against p53-MDM2/X interaction.
Rasafar N; Barzegar A; Mehdizadeh Aghdam E
Life Sci; 2020 Mar; 245():117358. PubMed ID: 32001262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
